.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX22_LoncastuximabTesirine.LoncastuximabTesirine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX22_LoncastuximabTesirine.LoncastuximabTesirine| name: | LoncastuximabTesirine | |
| ATC code: | L01FX22 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 150 | mg |
| volume of distribution: | 7.11 | L |
| clearance: | 0.524 | L/day |
| other parameters in model implementation | ||
Loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a CD19-directed monoclonal antibody conjugated to a cytotoxic pyrrolobenzodiazepine dimer. It is approved for use in adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Pharmacokinetic parameters reported in adults with relapsed or refractory diffuse large B-cell lymphoma. Data are based on population PK analysis of clinical trial subjects.